StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
000950.SZ$5.70-2.23%
Fair $5.70+0.0%

000950.SZ

C.Q. Pharmaceutical Holding Co., Ltd.

Healthcare / Medical DistributionShenzhen

$5.70

-0.13 (-2.23%)

Fairly Valued+0.0%Fair Value $5.70Fund rank 21/100 · Data gapFallback financials|
SA 34/D
F-Score: 7/9
High DebtLow Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 13%

FCF escenarios

weak_data · normalized FCF $264.1M · quality 23.0/100

Data gap 21/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 21/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

34/100

D

Piotroski

7/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 2unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Sector-specific holding-company NAV/SOTP model required: targets are disabled until look-through holdings, debt and discount data exists. Debt-to-Equity ratio is 2.00, above the 2.0 threshold ROE is 3.4%, below the 5% threshold
Thesis & Journal · 000950.SZLocal privado en este navegador · C.Q. Pharmaceutical Holding Co., Ltd.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$9.9B

P/E

22.8x

↑

EV/EBITDA

13.9x

↑

ROE

3.4%

↑

Gross Margin

7.2%

↓

Debt/Equity

2.00

↑
52-Week Range$6
$5$7

TradingView lightweight chart

000950.SZ price, volumen y niveles de valoración

Último $5.700Periodo +15.2%
Fair value: $5.700

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+6.7%

FCF CAGR

+194.8%

FCF margin

0.6%

FCF / Net income

1.18x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $82.45B · net income $386.7M · FCF $455.1M

2022-FY → 2025-FY

Gross margin

7.2%-1.4% pts

Operating margin

2.3%-1.2% pts

Net margin

0.5%-0.9% pts

FCF margin

0.6%+0.5% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$82.45B$82.45B$80.56B$78.40B$67.83B
Net Income$386.7M$386.7M$283.0M$624.6M$952.3M
EBITDA$1.91B$1.91B$2.16B$2.71B$3.00B
EPS0.220.220.160.360.55
Gross Margin7.2%7.2%7.4%8.0%8.6%
Operating Margin2.3%2.3%2.3%3.1%3.5%
Net Margin0.5%0.5%0.4%0.8%1.4%
Balance Sheet
Debt/Equity2.002.002.071.802.08
Current Ratio1.201.20———
Cash Flow
Free Cash Flow$455.1M$455.1M$-437.3M$264.1M$17.8M
Returns
ROE3.4%3.4%2.5%5.6%8.9%
Valuation
P/E22.8022.8031.3713.819.38
EV/EBITDA13.8613.8610.617.277.88
P/B0.870.870.780.770.84
Growth & Yield
Revenue Growth2.3%2.3%2.8%15.6%—
EPS Growth37.5%37.5%-55.6%-34.5%—
Dividend Yield1.1%1.1%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

32.0%

muy exigente

EPS terminal req.

$0.51

Spread vs growth

5.5%

5Y implied EPS CAGR

22.7%

exigente

EPS terminal req.

$0.61

Spread vs growth

14.8%

10Y implied EPS CAGR

16.2%

exigente

EPS terminal req.

$0.99

Spread vs growth

21.3%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +15.5%

Total return

+15.5%

Start / end P/E

31.1x → 25.9x

EPS bridge

0.16 → 0.22

Residual

-6.3%

EPS growth+37.5%
Multiple rerating-16.8%
Dividend+1.1%
Residual / FX / buybacks / cross-term-6.3%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.